Déjà Vu: GSK Recycles Its Problematic Adjuvant into Covid-19 Vaccines
GSK will embark on a Covid-19 vaccine joint effort with the French pharma giant, Sanofi. Under this “unprecedented” arrangement, Sanofi will provide the coronavirus antigen while GSK ponies up its trademark AS03 adjuvant system despite unresolved safety concerns.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed